The vascular endothelin system in obesity and type 2 diabetes: Pathophysiology and therapeutic implications

Life Sciences

Volumn 118, Issue 2, 2014, Pages 149-155

  Campia, Umberto ^a   Tesauro, Manfredi ^b   Di Daniele, Nicola ^b   Cardillo, Carmine ^c  

^a MedStar Diabetes Institute and MedStar Health Research Institute   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Endothelin; Insulin; Insulin resistance; Obesity; Type 2 diabetes

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; INSULIN; NITRIC OXIDE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; ENDOTHELIN;

ADIPOSE TISSUE; BIOLOGICAL ACTIVITY; ENDOTHELIAL DYSFUNCTION; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; REVIEW; VASODILATATION; ANIMAL; DIABETES MELLITUS, TYPE 2; METABOLISM; PATHOLOGY; VASCULAR ENDOTHELIUM;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE; OBESITY;

EID: 84942579693     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.02.028     Document Type: Review

References (65)

1. Ahlborg, G., Shemyakin, A., Bohm, F., Gonon, A., Pernow, J., Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care 30 (2007), 591–596.
2. Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009), 1640–1645.
3. American Heart Association, Statistical Fact Sheet 2013 Update. http://wwwheartorg/idc/groups/heart-public/wcm/sop/smd/documents/downloadable/ucm_319585pdf, 2013.
4. Arai, H., Hori, S., Aramori, I., Ohkubo, H., Nakanishi, S., Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 (1990), 730–732.
5. Barac, A., Campia, U., Panza, J.A., Methods for evaluating endothelial function in humans. Hypertension 49 (2007), 748–760.
6. Baron, A.D., Clark, M.G., Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 17 (1997), 487–499.
7. Barton, M., Yanagisawa, M., Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86 (2008), 485–498.
8. Bussey, C.T., Kolka, C.M., Rattigan, S., Richards, S.M., Adiponectin opposes endothelin-1-mediated vasoconstriction in the perfused rat hindlimb. Am J Physiol Heart Circ Physiol 301 (2011), H79–H86.
9. Campia, U., Tesauro, M., Cardillo, C., Human obesity and endothelium-dependent responsiveness. Br J Pharmacol 165 (2012), 561–573.
10. Cardillo, C., Kilcoyne, C.M., Waclawiw, M., Cannon, R.O. III, Panza, J.A., Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33 (1999), 753–758.
11. Cardillo, C., Nambi, S.S., Kilcoyne, C.M., Choucair, W.K., Katz, A., Quon, M.J., et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 100 (1999), 820–825.
12. Cardillo, C., Kilcoyne, C.M., Cannon, R.O., Panza, J.A., Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol 36 (2000), 1483–1488.
13. Cardillo, C., Campia, U., Bryant, M.B., Panza, J.A., Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106 (2002), 1783–1787.
14. Cardillo, C., Campia, U., Iantorno, M., Panza, J.A., Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 43 (2004), 36–40.
15. Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl J Med 334 (1996), 292–295.
16. Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M.E., Pratipanawatr, T., et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105 (2000), 311–320.
17. de Nucci, G., Thomas, R., D'Orleans-Juste, P., Antunes, E., Walder, C., Warner, T.D., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 85 (1988), 9797–9800.
18. Ferri, C., Bellini, C., Desideri, G., Baldoncini, R., Properzi, G., Santucci, A., et al. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes 105:Suppl. 2 (1997), 38–40.
19. Gao, Y.J., Zeng, Z.H., Teoh, K., Sharma, A.M., Abouzahr, L., Cybulsky, I., et al. Perivascular adipose tissue modulates vascular function in the human internal thoracic artery. J Thorac Cardiovasc Surg 130 (2005), 1130–1136.
20. Gao, Y.J., Lu, C., Su, L.Y., Sharma, A.M., Lee, R.M., Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol 151 (2007), 323–331.
21. Greenstein, A.S., Khavandi, K., Withers, S.B., Sonoyama, K., Clancy, O., Jeziorska, M., et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 119 (2009), 1661–1670.
22. Grundy, S.M., Brewer, H.B. Jr., Cleeman, J.I., Smith, S.C. Jr., Lenfant, C., Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004), 433–438.
23. Guvener, N., Aytemir, K., Aksoyek, S., Gedik, O., Plasma endothelin-1 levels in non-insulin dependent diabetes mellitus patients with macrovascular disease. Coron Artery Dis 8 (1997), 253–258.
24. Hajer, G.R., van Haeften, T.W., Visseren, F.L., Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29 (2008), 2959–2971.
25. Haslam, D.W., James, W.P., Obesity. Lancet 366 (2005), 1197–1209.
26. Haynes, W.G., Strachan, F.E., Webb, D.J., Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 92 (1995), 357–363.
27. Inyard, A.C., Chong, D.G., Klibanov, A.L., Barrett, E.J., Muscle contraction, but not insulin, increases microvascular blood volume in the presence of free fatty acid-induced insulin resistance. Diabetes 58 (2009), 2457–2463.
28. Ishibashi, K.I., Imamura, T., Sharma, P.M., Huang, J., Ugi, S., Olefsky, J.M., Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. J Clin Invest 107 (2001), 1193–1202.
29. Juan, C.C., Chuang, T.Y., Lien, C.C., Lin, Y.J., Huang, S.W., Kwok, C.F., et al. Leptin increases endothelin type A receptor levels in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 294 (2008), E481–E487.
30. Kim, J.A., Montagnani, M., Koh, K.K., Quon, M.J., Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006), 1888–1904.
31. Kohan, D.E., Pritchett, Y., Molitch, M., Wen, S., Garimella, T., Audhya, P., et al. Addition of atrasentan to renin–angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22 (2011), 763–772.
32. Kohno, M., Yasunari, K., Murakawa, K., Yokokawa, K., Horio, T., Fukui, T., et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 88 (1990), 614–618.
33. Lobato, N.S., Neves, K.B., Filgueira, F.P., Fortes, Z.B., Carvalho, M.H., Webb, R.C., et al. The adipokine chemerin augments vascular reactivity to contractile stimuli via activation of the MEK–ERK1/2 pathway. Life Sci 91 (2012), 600–606.
34. Lohn, M., Dubrovska, G., Lauterbach, B., Luft, F.C., Gollasch, M., Sharma, A.M., Periadventitial fat releases a vascular relaxing factor. FASEB J 16 (2002), 1057–1063.
35. Lteif, A., Vaishnava, P., Baron, A.D., Mather, K.J., Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 56 (2007), 728–734.
36. Mangiafico, R.A., Malatino, L.S., Santonocito, M., Spada, R.S., Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int Angiol 17 (1998), 97–102.
37. Mann, J.F., Green, D., Jamerson, K., Ruilope, L.M., Kuranoff, S.J., Littke, T., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21 (2010), 527–535.
38. Mather, K.J., Mirzamohammadi, B., Lteif, A., Steinberg, H.O., Baron, A.D., Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 51 (2002), 3517–3523.
39. Mohamed-Ali, V., Pinkney, J.H., Coppack, S.W., Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22 (1998), 1145–1158.
40. Muniyappa, R., Montagnani, M., Koh, K.K., Quon, M.J., Cardiovascular actions of insulin. Endocr Rev 28 (2007), 463–491.
41. Ohkita, M., Takaoka, M., Shiota, Y., Nojiri, R., Matsumura, Y., Nitric oxide inhibits endothelin-1 production through the suppression of nuclear factor kappa B. Clin Sci 103:Suppl. 48 (2002), 68S–71S.
42. Ottosson-Seeberger, A., Lundberg, J.M., Alvestrand, A., Ahlborg, G., Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol Scand 161 (1997), 211–220.
43. Pasarica, M., Sereda, O.R., Redman, L.M., Albarado, D.C., Hymel, D.T., Roan, L.E., et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 58 (2009), 718–725.
44. Piatti, P.M., Monti, L.D., Conti, M., Baruffaldi, L., Galli, L., Phan, C.V., et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45 (1996), 316–321.
45. Potenza, M.A., Marasciulo, F.L., Chieppa, D.M., Brigiani, G.S., Formoso, G., Quon, M.J., et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 289 (2005), H813–H822.
46. Quehenberger, P., Exner, M., Sunder-Plassmann, R., Ruzicka, K., Bieglmayer, C., Endler, G., et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 90 (2002), 711–718.
47. Rafnsson, A., Bohm, F., Settergren, M., Gonon, A., Brismar, K., Pernow, J., The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia 55 (2012), 600–608.
48. Rask-Madsen, C., King, G.L., Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 25 (2005), 487–496.
49. Saito, Y., Nakao, K., Mukoyama, M., Imura, H., Increased plasma endothelin level in patients with essential hypertension. N Engl J Med, 322, 1990, 205.
50. Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K., et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348 (1990), 732–735.
51. Schinzari, F., Tesauro, M., Rovella, V., Galli, A., Mores, N., Porzio, O., et al. Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. Am J Physiol Endocrinol Metab 299 (2010), E947–E952.
52. Schinzari, F., Tesauro, M., Rovella, V., Di Daniele, N., Mores, N., Veneziani, A., et al. Leptin stimulates both endothelin-1 and nitric oxide activity in lean subjects but not in patients with obesity-related metabolic syndrome. J Clin Endocrinol Metab 98 (2013), 1235–1241.
53. Seo, B., Oemar, B.S., Siebenmann, R., von Segesser, L., Luscher, T.F., Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89 (1994), 1203–1208.
54. Shemyakin, A., Salehzadeh, F., Bohm, F., Al-Khalili, L., Gonon, A., Wagner, H., et al. Regulation of glucose uptake by endothelin-1 in human skeletal muscle in vivo and in vitro. J Clin Endocrinol Metab 95 (2010), 2359–2366.
55. Soltis, E.E., Cassis, L.A., Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens A 13 (1991), 277–296.
56. Stow, L.R., Jacobs, M.E., Wingo, C.S., Cain, B.D., Endothelin-1 gene regulation. FASEB J 25 (2011), 16–28.
57. Tesauro, M., Schinzari, F., Rovella, V., Di Daniele, N., Lauro, D., Mores, N., et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 54 (2009), 995–1000.
58. Vicent, D., Ilany, J., Kondo, T., Naruse, K., Fisher, S.J., Kisanuki, Y.Y., et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 111 (2003), 1373–1380.
59. Wagner, O.F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P.J., et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267 (1992), 16066–16068.
60. Wallace, A.M., McMahon, A.D., Packard, C.J., Kelly, A., Shepherd, J., Gaw, A., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104 (2001), 3052–3056.
61. Watts, S.W., Dorrance, A.M., Penfold, M.E., Rourke, J.L., Sinal, C.J., Seitz, B., et al. Chemerin connects fat to arterial contraction. Arterioscler Thromb Vasc Biol 33 (2013), 1320–1328.
62. Weil, B.R., Westby, C.M., Van Guilder, G.P., Greiner, J.J., Stauffer, B.L., DeSouza, C.A., Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 301 (2011), H689–H695.
63. Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001), 1930–1935.
64. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988), 411–415.
65. Yudkin, J.S., Eringa, E., Stehouwer, C.D., “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365 (2005), 1817–1820.